As the President of iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, Stacey has successfully solidified the companys position as a vanguard on the forefront of cancer detection and treatment. While successfully navigating the company through the 2020 COVID pandemic, she maximized organizational effectiveness, developed a winning commercial infrastructure, and fortified the companys financial strength, resulting in strong performance across a wide range of metrics, while at the same time, positioning the company for future growth.
With more than twenty years of experience in the medical technology industry, Stacey effectively led iCAD through multiple successful global product launches, including the release of ProFound AI® for Digital Breast Tomosynthesis (DBT), the worlds first FDA cleared artificial intelligence (AI) software for 3D mammography, and ProFound AI® Risk, the worlds first short-term breast cancer risk assessment solution.
This results-oriented leader demonstrated a proven ability to promote change and business transformation on a global level, as she drove the development of multiple new clinical applications for iCADs targeted radiation platform, the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, which is FDA cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast and gynecological cancers as well as nonmelanoma skin cancer. During her tenure as President of iCAD, Stacey strategically targeted large market opportunities to explore the use of the Xoft System in the treatment of other types of cancers, including brain tumors, where the Companys technology is showing promise in being able to extend the lives of patients afflicted with this deadly cancer, and significantly impact the companys growth in the years ahead.